3Helix CHP Indication: Multiple Myeloma

Visualizing Collagen Remodeling in Multiple Myeloma

3Helix Logo

Introduction

3Helix Collagen Hybridizing Peptides (CHPs) are short peptides that selectively target damaged and remodeling collagen for applications in therapeutics, cosmetics, drug delivery systems, and life science tools.

Summary

Multiple Myeloma Indication: Collagen Hybridizing Peptides (CHPs) can monitor collagen degradation in multiple myeloma, crucial for understanding the disease's progression and response to treatment.

Indication Note

Assess Osteolytic Bone Lesions in Multiple Myeloma with Collagen Hybridizing Peptides (CHPs).

Multiple myeloma (MM) involves the uncontrolled proliferation of plasma cells in the bone marrow, often accompanied by bone marrow fibrosis, characterized by abnormal collagen deposition.

Collagen Hybridizing Peptides (CHPs) selectively bind and quantify denatured collagen, a powerful tool for researchers looking to:

  • Accelerate Preclinical Drug Development by improving in vivo imaging of osteolytic bone lesions in mouse models, compared to micro-CT.
  • Decipher the complex role of ECM remodeling by directly visualizing protease-degraded collagen within the multiple myeloma bone marrow microenvironment.
Graphic showing how CHPs bind with damaged collagen.

Ilex Life Sciences LLC is an authorized distributor of CHP products manufactured by 3Helix, Inc.